https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Mediation effect of neutrophil lymphocyte ratio on cardiometabolic risk factors and cardiovascular events https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:45164 Wed 26 Oct 2022 14:11:30 AEDT ]]> Progression of chronic kidney disease: an illness-death model approach https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:30809 Wed 23 Feb 2022 16:03:23 AEDT ]]> The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:38721 Wed 19 Jan 2022 09:36:02 AEDT ]]> Prognostic factors of all-cause mortalities in continuous ambulatory peritoneal dialysis: a cohort study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19471  2.19 adds no further benefit. Serum albumin, hemoglobin, SBP, and UF volume are also associated with mortality. However, our study may face with selection and other unobserved confounders, so further randomized controlled trials are required to confirm these cutoffs.]]> Wed 11 Apr 2018 14:03:21 AEST ]]> Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:48300 Tue 14 Mar 2023 14:13:43 AEDT ]]> Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease. https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:43136 Tue 13 Sep 2022 15:14:51 AEST ]]> Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:51430 Tue 05 Sep 2023 17:47:25 AEST ]]> Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:49456 Thu 18 May 2023 12:19:12 AEST ]]> How and whom to monitor for seizures in an ICU: a systematic review and meta-analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:42115 Thu 18 Aug 2022 14:21:19 AEST ]]> Periodontitis as the risk factor of chronic kidney disease: mediation analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:36550 Thu 17 Feb 2022 09:26:35 AEDT ]]> Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:11389 Sat 24 Mar 2018 08:10:00 AEDT ]]> Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:4618 Sat 24 Mar 2018 07:21:53 AEDT ]]> Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:49386 Fri 12 May 2023 14:27:07 AEST ]]> Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:53517 Fri 01 Dec 2023 11:12:49 AEDT ]]> Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:31991 1 year (RAAS2). An augmented inverse-probability weighting (AIPW) method was used to estimate potential-outcome mean (POM) and average treatment-effect (ATE). Multi-logit and Poisson regressions were used for treatment and outcome models, respectively. Analyses were stratified by ESRD, death before/after ESRD for diabetic and non-diabetic groups. STATA 14.0 was used for statistical analyses. Results: Among 15,032 diabetic patients, 2346 (15.6%), 2351 (18.5%), and 1607 (68.5%) developed ESRD, died before ESRD, and died after ESRD, respectively. Only RAAS2 effect was significant on ESRD, death before and after ESRD. The ESRD rates were 12.9%, versus 20.0% for RAAS2 and non-RAAS, respectively, resulted in significant risk differences (RD) of -7.2% (95% CI: -8.8%, -5.5%), and a numbers needed-to-treat (NNT) of 14. Death rates before ESRD for these corresponding groups were 14.4% (12.9%, 15.9%) and 19.6% (18.7%, 20.4%) with a NNT of 19. Death rates after ESRD in RAAS2 was lower than non-RASS group (i.e., 62.8% (55.5%, 68.9%) versus 68.1% (65.9%, 70.4%)) but this was not significant. RAAS2 effects on ESRD and death before ESRD were persistently significant in non-diabetic patients (n = 17,074) but not for death after ESRD with the NNT of about 15 and 16 respectively. Conclusions: Receiving RAAS blockade for 1 year or longer could prevent both CKD progression to ESRD and premature mortality.]]> Fri 01 Apr 2022 09:26:45 AEDT ]]>